Delving into the Latest Updates on LAT-8881 with Synapse

Overview

Basic Info

Drug Type

Chemical drugs, Peptides

Synonyms

AOD-9604, AOD9604, TYR-HGH171191

Target

GHR x LANCL1

Action

agonists

Mechanism

GHR agonists(Growth hormone receptor agonists), LANCL1 agonists(LanC like 1 agonists)

Therapeutic Areas

Nervous System DiseasesOther Diseases

Active Indication

Neuralgia

Inactive Indication

Acute migraineDiabetic peripheral neuropathyLumbar Radiculopathy+ [4]

Originator Organization

Mesoestetic Sl

Active Organization

Lateral Pharma Pty Ltd.

Inactive Organization

Metabolic Pharmaceuticals Pty Ltd.

License Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC78H123N23O23S2

InChIKeyGVIYUKXRXPXMQM-BPXGDYAESA-N

CAS Registry221231-10-3

Sequence Code 86160

Source: *****

The study consists of two parts. Part A will evaluate the safety and tolerability of intravenous LAT8881 in healthy volunteers using an ascending dose schedule. Part B will evaluate the analgesic efficacy of a single intravenous dose of LAT8881, compared with placebo, in patients with lumbar radicular pain.
Healthy volunteers are not accepted for Part B.

Start Date17 May 2022

Sponsor / Collaborator

Lateral Pharma Pty Ltd.

[+1]

ACTRN12619001369112

/ CompletedPhase 2

A proof of concept study of the efficacy and safety of oral LAT8881 in acute migraine

Start Date04 Oct 2019

Sponsor / Collaborator

Lateral Pharma Pty Ltd.

NCT04153409

/ CompletedPhase 2

A Proof of Concept Study of the Efficacy and Safety of Oral LAT8881 in Acute Migraine

This is a randomised, placebo controlled, double blind, crossover proof of concept study to investigate the efficacy and safety of oral LAT8881 in acute migraine, with or without aura.

Start Date24 Sep 2019

Sponsor / Collaborator

Lateral Pharma Pty Ltd.

100 Clinical Results associated with LAT-8881

Login to view more data

100 Translational Medicine associated with LAT-8881

Login to view more data

100 Patents (Medical) associated with LAT-8881

Login to view more data

28

Literatures (Medical) associated with LAT-8881

16 Aug 2024·The Journal of infectious diseases

Harnessing Endogenous Peptide Compounds as Potential Therapeutics for Severe Influenza

Article

Author: Tate, Michelle D ; Ely, Lauren K ; Harpur, Christopher M ; West, Alison C ; Gearing, Andrew J ; Le Page, Mélanie A ; Hodges, Christopher ; Lam, Maggie

Abstract:

Background:

Excessive pulmonary inflammation and damage are characteristic features of severe influenza virus infections. LAT8881 is a synthetic 16–amino acid cyclic peptide form of a naturally occurring C-terminal fragment of human growth hormone with therapeutic efficacy against influenza. Shorter linear peptides are typically easier to manufacture and formulate for delivery than larger cyclic peptides. A 6–amino acid linear peptide fragment of LAT8881, LAT9997, was investigated as a potential influenza therapy.

Methods:

LAT9997 was evaluated for its potential to limit disease in a preclinical mouse model of severe influenza infection.

Results:

Intranasal treatment of mice with either LAT8881 or LAT9997 from day 1 following influenza infection significantly improved survival outcomes. Initiating LAT9997 treatment at the onset of severe disease also significantly improved disease severity. Greater disease resistance in LAT9997-treated mice correlated with reduced lung immunopathology, damage markers, vascular leak, and epithelial cell death. Treatment reduced viral loads, cytokines, and neutrophil infiltration in the airways yet maintained protective alveolar macrophages in a dose-dependent manner. Sequential trimming of N- and C-terminal amino acids from LAT9997 revealed a structure-activity relationship.

Conclusions:

These findings provide preclinical evidence that therapeutic LAT9997 treatment limits viral burden and characteristic features of severe influenza, including hyperinflammation and lung damage.

Summary:

Excessive pulmonary inflammation and damage are characteristic features of severe influenza virus infections. LAT9997 is a linear peptide fragment derived from human growth hormone. This study provides preclinical evidence that therapeutic LAT9997 treatment limits viral burden, hyperinflammation, and lung damage.

01 Jan 2023·Clinical & translational immunology

Naturally derived cytokine peptides limit virus replication and severe disease during influenza A virus infection

Article

Author: Alison C West ; Mélanie A Le Page ; Maggie Lam ; Osezua Oseghale ; Christopher M Harpur ; Christopher Hodges ; Michelle D Tate ; Andrew J Gearing

Abstract:

Objectives:

Novel host‐targeted therapeutics could treat severe influenza A virus (IAV) infections, with reduced risk of drug resistance. LAT8881 is a synthetic form of the naturally occurring C‐terminal fragment of human growth hormone. Acting independently of the growth hormone receptor, it can reduce inflammation‐induced damage and promote tissue repair in an animal model of osteoarthritis. LAT8881 has been assessed in clinical trials for the treatment of obesity and neuropathy and has an excellent safety profile. We investigated the potential for LAT8881, its metabolite LAT9991F and LAT7771 derived from prolactin, a growth hormone structural homologue, to treat severe IAV infection.

Methods:

LAT8881, LAT9991F and LAT7771 were evaluated for their effects on cell viability and IAV replication in vitro, as well as their potential to limit disease in a preclinical mouse model of severe IAV infection.

Results:

In vitro LAT8881 treatment enhanced cell viability, particularly in the presence of cytotoxic stress, which was countered by siRNA inhibition of host lanthionine synthetase C‐like proteins. Daily intranasal treatment of mice with LAT8881 or LAT9991F, but not LAT7771, from day 1 postinfection significantly improved influenza disease resistance, which was associated with reduced infectious viral loads, reduced pro‐inflammatory cytokines and increased abundance of protective alveolar macrophages. LAT8881 treatment in combination with the antiviral oseltamivir phosphate led to more pronounced reduction in markers of disease severity than treatment with either compound alone.

Conclusion:

These studies provide the first evidence identifying LAT8881 and LAT9991F as novel host‐protective therapies that improve survival, limit viral replication, reduce local inflammation and curtail tissue damage during severe IAV infection. Evaluation of LAT8881 and LAT9991F in other infectious and inflammatory conditions of the airways is warranted.

01 Aug 2022·Journal of chromatography. A

Multi-analyte screening of small peptides by alkaline pre-activated solid phase extraction coupled with liquid chromatography-high resolution mass spectrometry in doping controls

Article

Author: Jing, Jing ; Wang, Yang ; Xu, Xin ; Tian, Tian ; Shan, Yuanhong

Peptidic drugs with wide spectrum of physiological activity are of interest for cheating athletes and can be misused as doping in sports. A growing number of small peptide drugs capable of enhancing performance are included in the prohibited list issued by World Anti-Doping Agency (WADA), therefore the improvement of the detection methods is constantly needed. In the present study, a screening assay was developed comprising 54 prohibited small peptides and the related substances in urine by means of the alkaline pre-activated weak cation exchange-solid phase extraction (WCX-SPE) with liquid chromatography-high resolution mass spectrometry (LCHRMS). This method performed good enrichment and purification effect of traditional WCX for basic peptides, and also improve the purification power of acidic peptides, which significantly expanded the coverage of detection substances. The method was validated in accordance with WADA relevant criteria and validated with a main focus on qualitative parameters including selectivity, limits of detection (0.02-0.2 ng/mL), linearity (0.1-20 ng/mL for 46 analytes and 0.2-20 ng/mL for 9 analytes), accuracy and precision (RE% and RSD% < 20% at 1, 5 and 10 ng/mL), recovery (39.2%-100.1% except for the TB500(1-2) free acid: 9.2%), matrix effects (ion suppression effect: 0 to 49.4% and ion enhancement effect: 100% and 264.6%), carryover, reliability and sample extract stability. As a proof-of-principle, urine samples from two patients received a single injection of leuprorelin acetate microspheres (3.75 mg) 30 days before were analyzed and the results proved the applicability of the method.

1

News (Medical) associated with LAT-8881

16 Jun 2026

·www.prnewswire.com

Peer-reviewed publication shows that Lateral pharma's SCP drugs for neuropathic pain act via the novel target LanCL1

MELBOURNE, Australia, June 11, 2026 /PRNewswire/ -- Lateral Pharma today announced the publication of peer-reviewed research in PAIN, a leading journal dedicated to pain research, identifying Lanthionine Synthetase C-Like Protein 1 (LanCL1) as a novel therapeutic target for neuropathic pain. The LanCL family of proteins are responsive to Lateral Pharma's Stressed Cell Protectant (SCP) drugs. The publication, titled "Lanthionine synthetase C-like protein 1 (LanCL1): a therapeutic target for neuropathic pain," shows that LAT8881, Lateral Pharma's first-generation SCP peptide and several other SCP peptides, act via LanCL1 and offers new insights into the biology underlying neuropathic pain. Painful Neuropathy caused by diabetes, injury, chemotherapy and some viral infections affects hundreds of millions of people worldwide. Existing therapies provide no benefit in at least half of the patients and have dose-limiting side effects or tolerability concerns, highlighting the need for new approaches. "This publication marks a pivotal milestone in advancing the biology of neuropathic pain and in accelerating Lateral Pharma's mission. Chronic neuropathic pain is a distressing and debilitating condition that affects around 10% of the population. By identifying LanCL1 as a novel therapeutic target and demonstrating drug activity through this pathway, the research delivers compelling scientific validation for Lateral Pharma's Stressed Cell Protectant platform and its potential to address major unmet medical needs." said David Kenley, Chief Executive Officer of Lateral Pharma. The publication is consistent with Lateral Pharma's Phase 1b study in patients with chronic lumbar radicular pain (sciatica) that showed a single intravenous dose of LAT8881 was safe and well tolerated while demonstrating clinically meaningful reductions in provoked pain. The findings also complement recently published research in Mucosal Immunology demonstrating that LAT9997, Lateral Pharma's lead SCP peptide, significantly improved survival and reduced lung injury in preclinical models of influenza-associated bacterial pneumonia. In that study, two intranasal doses of LAT9997 administered during the early stages of influenza infection improved survival from 0% in control animals to 85% in treated animals, highlighting the broader therapeutic potential of LanCL-targeted therapies beyond neuropathic pain. The growing body of evidence supporting SCP therapeutics is further reinforced by Lateral Pharma's intellectual property portfolio, including a United States Patent and Trademark Office (USPTO) granted composition-of-matter patent covering LAT9997 for the treatment of neuropathic pain. About Lateral Pharma Lateral Pharma is an Australian biotechnology company developing a new class of therapeutics based on the activation of LanCL pathways involved in cellular protection, repair and recovery. The Company is focused on addressing significant unmet medical needs supported by positive data in models of neuropathic pain, neurodegeneration, infectious respiratory disease and healthy longevity. The publication was authored by researchers from Monash University, the University of Warwick, the University of Bristol, Pacific Discovery Services, Evotec and Lateral Pharma, and is now available online through PAIN. Publication Spanswick DC et al. Lanthionine synthetase C-like protein 1 (LanCL1): a therapeutic target for neuropathic pain. PAIN. 2026. Related Publication West AC et al. Short-course intranasal LAT9997 therapy limits post-influenza bacterial pneumonia by recalibrating lung immunity. Mucosal Immunology. 2026. SOURCE Lateral Pharma 21% more press release views with Request a Demo

Phase 1

100 Deals associated with LAT-8881

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute migraine	Phase 2	Australia	Lateral Pharma Pty Ltd.	24 Sep 2019
Diabetic peripheral neuropathy	Phase 2	Australia	Lateral Pharma Pty Ltd.	09 Apr 2019
Diabetic peripheral neuropathy	Phase 2	United Kingdom	Lateral Pharma Pty Ltd.	09 Apr 2019
Neuralgia, Postherpetic	Phase 2	Australia	Lateral Pharma Pty Ltd.	09 Apr 2019
Neuralgia, Postherpetic	Phase 2	United Kingdom	Lateral Pharma Pty Ltd.	09 Apr 2019
Neuralgia	Phase 2	Australia	Lateral Pharma Pty Ltd.	-
Obesity	Phase 2	Australia	Metabolic Pharmaceuticals Pty Ltd.	-
Lumbar Radiculopathy	Phase 1	Australia	Lateral Pharma Pty Ltd.	17 May 2022
Radicular Pain	Phase 1	Australia	Lateral Pharma Pty Ltd.	17 May 2022
Osteoporosis	Preclinical	Australia	-	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05298306 (CTgov)	Phase 1	Lumbar Radiculopathy \| Radicular Pain	26	LAT8881 (LAT8881)	tsobjbaccx(vwammnjqzg) = donqkeoizx sgrqnbuzbh (qqeuufuqot, 2.7) View more	-	27 Nov 2024
				Placebo (Placebo)	tsobjbaccx(vwammnjqzg) = huqpugkcyg sgrqnbuzbh (qqeuufuqot, 2.3) View more
NCT03865953 (CTgov)	Phase 2	Neuralgia, Postherpetic \| Diabetic peripheral neuropathy	53	LAT8881 (LAT8881)	cgujfkbjwb(bhtyuiscwi) = idwxsebtae xkthkdseyl (tevshfbhxe, 1.53) View more	-	23 Apr 2021
				Placebo (Placebo)	cgujfkbjwb(bhtyuiscwi) = skqucguvdr xkthkdseyl (tevshfbhxe, 2.09) View more
NCT04153409 (CTgov)	Phase 2	Acute migraine	21	LAT8881 (Active)	wtcbhttwbm(gayatobcld) = fdjlpiegzr wybdrdbenz (rajpajabim, 1.10) View more	-	30 Mar 2021
				Placebo (Placebo)	wtcbhttwbm(gayatobcld) = yzuzwnecuv wybdrdbenz (rajpajabim, 1.33) View more